Back to Search
Start Over
A protocol for cell therapy infusion in neonates
- Source :
- Stem Cells Translational Medicine, Vol 10, Iss 5, Pp 773-780 (2021), Stem Cells Translational Medicine
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Cell therapies for neonatal morbidities are progressing to early phase clinical trials. However, protocols for intravenous (IV) delivery of cell therapies to infants have not been evaluated. It has been assumed the cell dose prescribed is the dose delivered. Early in our clinical trial of human amnion epithelial cells (hAECs), we observed cells settling in the syringe and IV tubing used to deliver the suspension. The effect on dose delivery was unknown. We aimed to quantify this observation and determine an optimal protocol for IV delivery of hAECs to extremely preterm infants. A standard pediatric infusion protocol was modeled in the laboratory. A syringe pump delivered the hAEC suspension over 60 minutes via a pediatric blood transfusion set (200‐μm filter and 2.2 mL IV line). The infusion protocol was varied by agitation methods, IV‐line volumes (0.2‐2.2 mL), albumin concentrations (2% vs 4%), and syringe orientations (horizontal vs vertical) to assess whether these variables influenced the dose delivered. The influence of flow rate (3‐15 mL/h) was assessed after other variables were optimized. The standard infusion protocol delivered 17.6% ± 9% of the intended hAEC dose. Increasing albumin concentration to 4%, positioning the syringe and IV line vertically, and decreasing IV‐line volume to 0.6 mL delivered 99.7% ± 13% of the intended hAEC dose. Flow rate did not affect dose delivery. Cell therapy infusion protocols must be considered. We describe the refinement of a cell infusion protocol that delivers intended cell doses and could form the basis of future neonatal cell delivery protocols.<br />Cell therapy is neonatal medicine's new frontier. While the challenges of translation have been much discussed, we have overlooked a simple yet fundamental hurdle; a protocol that delivers the intended cell dose intravenously to infants. Our existing protocol delivered less than 20% of the intended dose of human amnion epithelial cells. Here, we demonstrate simple measures can optimize cell dose delivery.
- Subjects :
- 0301 basic medicine
Blood transfusion
medicine.medical_treatment
Cell- and Tissue-Based Therapy
infant, premature
infusions, intravenous
Cell therapy
03 medical and health sciences
0302 clinical medicine
Albumins
bronchopulmonary dysplasia
medicine
Humans
Amnion
lcsh:QH573-671
Syringe
Syringe driver
lcsh:R5-920
business.industry
lcsh:Cytology
Syringes
Albumin
Infant, Newborn
Epithelial Cells
Cell Biology
General Medicine
medicine.disease
Clinical trial
Standards, Protocols, Policies, and Regulations for Cell‐based Therapies
030104 developmental biology
medicine.anatomical_structure
Bronchopulmonary dysplasia
Anesthesia
cell‐ and tissue‐based therapy
business
lcsh:Medicine (General)
human amnion epithelial cells
030217 neurology & neurosurgery
Developmental Biology
Subjects
Details
- Language :
- English
- ISSN :
- 21576564 and 21576580
- Volume :
- 10
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Stem Cells Translational Medicine
- Accession number :
- edsair.doi.dedup.....9206784f9523bed3f26b47b74ade6470